Dr Reddy's launches Zenatane in US

The company has launched generic Accutane in strengths of 20 mg and 40 mg on March 28 following the approval

Hyderabad-based pharmaceutical major Dr Reddy’s Laboratories (DRL) stated that it has launched Zenatane in 20 mg and 40 mg in the US following its approval by the United States Food & Drug Administration (USFDA).

Zenatane, used for the treatment of acne, is a therapeutically-equivalent generic version of Accutane (Isotretinoin capsules USP) in the US market.

The total value of the drug sales in the US was approximately $309 million for the 12 month-ending January 2013, according to IMS Health.

DRL’s Zenatane capsules will be available in boxes of 30 (three prescription packs of 10 capsules).

This comes just weeks after Dr Reddy’s announced that it had launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa (zoledronic acid) 4 mg/5 ml injection in the US market  March 4, 2013.

Dr Reddy’s Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.